Blank Fax Cover Sheet Hiberix® Clinical Training Presented by Joanna by rfu13167

VIEWS: 99 PAGES: 9

More Info
									          Hiberix®
          Clinical
          Training
    Presented by Joanna Briggs, R.N.
Clinical/Quality &Compliance Coordinator
          Immunization Section
  Community and Public Health Division
           Update on Haemophilus
       influenzae type b (Hib) Vaccine
                  Shortage
• National Hib shortage began in late 2007.
• As of October 2009, all Hib vaccines are
  allocated to Immunization grantees by the
  Centers for Disease Control and Prevention
  (CDC).
• Hib vaccine allocations will continue until
  there is adequate Hib vaccine supply.
                        Hib Vaccines --
                  Differences and Guidelines
• PedvaxHIB® (Merck)
    – Schedule:
        • 2 doses at least 4 weeks apart (8 weeks preferred). Series should not be
          started earlier than 6 weeks of age.
        • Currently, the limited supply of PedvaxHIB® allocated to Wyoming is
          being shipped directly to Indian Health Services.
• ActHIB® (sanofi pasteur)
    – Schedule:
        • 3 doses at least 4 weeks apart (8 weeks preferred). Series should not be
          started earlier than 6 weeks of age.
•   Pentacel® (sanofi pasteur) includes:
    – DTaP (Daptacel®)
    – IPV (IPOL®)
    – Hib (ActHIB®)
        • Series is 3 doses at age 2 months, 4 months, 6 months and 12-15
          months.

•
    Hiberix® (GSK)
•
Hiberix® (GSK) – cont.
                        Prescribing Information
• Indication and Usage:
   – Booster dose for the prevention of Haemophilus influenzae type b for
     children 15 months through 4 years of age (prior to the 5th birthday).
   – Use only as a booster doses in children who have received a primary series.
     (Primary series: ActHIB=3 doses; PedvaxHib=2 doses; Pentacel=3 doses.)
   – Inspect vials and syringes before reconstituting and then only administered a
     clear and colorless reconstituted solution.
       • Shake solution vigorously before injecting.
• As of October 2009, all children under age 5 years need a
  completed series of Hib that includes a booster.
• Additional information for providers who serve American Indian
  and Alaska Native children is available at:
  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm56d1219a1.htm.
• Applicable codes for Hiberix:
   – WyIR code: PRP-T -- CPT code -- 90648 CVX code -- 48
                 Safety Information
• In clinical studies, adverse events in children
  receiving Hiberix® included:
  – Pain and redness at injection site; fever; fussiness;
    loss of appetite; and restlessness.
• Severe allergic reaction (eg, anaphylaxis)
  after previous dose of any Hib or tetanus
  toxoid-containing vaccine or component is a
  contraindication.
             Additional Resources
• CDC’s Morbidity and Mortality Weekly Report
  (MMWR), dated September 18, 2009
  – http://www.cdc.gov/mmwr/preview/mmwrhtml/m
    m5836a5.htm
• Hiberix® Package Insert
  – http://www.fda.gov/downloads/BiologicsBloodV
    accines/Vaccines/ApprovedProducts/UCM17953
    0.pdf
• Hiberix® Web Site:
  – http://www.hiberix.com/
            Please answer these questions on a blank piece of paper
              and fax your answers to 307-673-5368. Please include
            your name and PIN on the fax cover sheet – and indicate
             “Hiberix training competency” on your fax cover sheet.
               Once received, Hiberix shipments can be authorized.

1. The antigen contained in Hiberix® is ___________.
2. Hiberix® should never be administered after age __________ or before
   ________ months.
3. Hib booster doses are authorized for all children as of October 2009.
   TRUE         FALSE
4. Adverse events in children receiving Hiberix include: a. ___________
   b.______________ c.______________ .
5. Diluents (saline) may be exchanged with other vaccines needing
   reconstituted.
    TRUE        FALSE
6. Hiberix® lyophilized power should be stored in the ______________ and
   protected from ____________ .

								
To top